Surgical treatment of prostate cancer

Timothy Masterson, James A. Masterson

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Introduction Prostate cancer is the most common cancer and the second most common cause of cancer-related death of American men [1]. The American Cancer Society estimates that 186,320 new cases of prostate cancer will be diagnosed and that 28,660 men will die from this disease in the United States in 2008 [2]. The widespread use of prostate-specific antigen (PSA) for prostate cancer screening has led to a substantial decrease in stage at time of diagnosis. Data from the National Cancer Institute's Surveillance, Epidemiology, and End Results program reveal that 91% of diagnosed cancers in the period 1996–2002 were localized to the prostate [1], whereas only 80% are seen in series from previous years. The 5-year expected survival for prostate cancers diagnosed between 1996 and 2002 is 100%, up substantially from 76% between 1984 and 1986 [1]. With today's patients presenting at a younger age and with cancers at a lower stage and lower grade, the management of clinically localized prostate cancer has focused on decreasing the inherent morbidity and long-term consequences of specific therapies. Selecting the optimal therapeutic approach from an array of choices requires individualization of treatment plans based upon risk stratification, the effectiveness of the treatment, and the likelihood that a patient will experience a treatment-related complication. Radical prostatectomy (RP) remains an excellent treatment option for men with clinically localized prostate cancer.

Original languageEnglish (US)
Title of host publicationProstate Cancer
PublisherCambridge University Press
Pages43-57
Number of pages15
ISBN (Print)9780511551994, 9780521887045
DOIs
StatePublished - Jan 1 2008
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Therapeutics
SEER Program
Neoplasms
Second Primary Neoplasms
National Cancer Institute (U.S.)
Prostate-Specific Antigen
Prostatectomy
Early Detection of Cancer
Prostate
Morbidity
Survival

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Masterson, T., & Masterson, J. A. (2008). Surgical treatment of prostate cancer. In Prostate Cancer (pp. 43-57). Cambridge University Press. https://doi.org/10.1017/CBO9780511551994.006

Surgical treatment of prostate cancer. / Masterson, Timothy; Masterson, James A.

Prostate Cancer. Cambridge University Press, 2008. p. 43-57.

Research output: Chapter in Book/Report/Conference proceedingChapter

Masterson, T & Masterson, JA 2008, Surgical treatment of prostate cancer. in Prostate Cancer. Cambridge University Press, pp. 43-57. https://doi.org/10.1017/CBO9780511551994.006
Masterson T, Masterson JA. Surgical treatment of prostate cancer. In Prostate Cancer. Cambridge University Press. 2008. p. 43-57 https://doi.org/10.1017/CBO9780511551994.006
Masterson, Timothy ; Masterson, James A. / Surgical treatment of prostate cancer. Prostate Cancer. Cambridge University Press, 2008. pp. 43-57
@inbook{a13e73a2aaa74d54926e08a3948ad983,
title = "Surgical treatment of prostate cancer",
abstract = "Introduction Prostate cancer is the most common cancer and the second most common cause of cancer-related death of American men [1]. The American Cancer Society estimates that 186,320 new cases of prostate cancer will be diagnosed and that 28,660 men will die from this disease in the United States in 2008 [2]. The widespread use of prostate-specific antigen (PSA) for prostate cancer screening has led to a substantial decrease in stage at time of diagnosis. Data from the National Cancer Institute's Surveillance, Epidemiology, and End Results program reveal that 91{\%} of diagnosed cancers in the period 1996–2002 were localized to the prostate [1], whereas only 80{\%} are seen in series from previous years. The 5-year expected survival for prostate cancers diagnosed between 1996 and 2002 is 100{\%}, up substantially from 76{\%} between 1984 and 1986 [1]. With today's patients presenting at a younger age and with cancers at a lower stage and lower grade, the management of clinically localized prostate cancer has focused on decreasing the inherent morbidity and long-term consequences of specific therapies. Selecting the optimal therapeutic approach from an array of choices requires individualization of treatment plans based upon risk stratification, the effectiveness of the treatment, and the likelihood that a patient will experience a treatment-related complication. Radical prostatectomy (RP) remains an excellent treatment option for men with clinically localized prostate cancer.",
author = "Timothy Masterson and Masterson, {James A.}",
year = "2008",
month = "1",
day = "1",
doi = "10.1017/CBO9780511551994.006",
language = "English (US)",
isbn = "9780511551994",
pages = "43--57",
booktitle = "Prostate Cancer",
publisher = "Cambridge University Press",

}

TY - CHAP

T1 - Surgical treatment of prostate cancer

AU - Masterson, Timothy

AU - Masterson, James A.

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Introduction Prostate cancer is the most common cancer and the second most common cause of cancer-related death of American men [1]. The American Cancer Society estimates that 186,320 new cases of prostate cancer will be diagnosed and that 28,660 men will die from this disease in the United States in 2008 [2]. The widespread use of prostate-specific antigen (PSA) for prostate cancer screening has led to a substantial decrease in stage at time of diagnosis. Data from the National Cancer Institute's Surveillance, Epidemiology, and End Results program reveal that 91% of diagnosed cancers in the period 1996–2002 were localized to the prostate [1], whereas only 80% are seen in series from previous years. The 5-year expected survival for prostate cancers diagnosed between 1996 and 2002 is 100%, up substantially from 76% between 1984 and 1986 [1]. With today's patients presenting at a younger age and with cancers at a lower stage and lower grade, the management of clinically localized prostate cancer has focused on decreasing the inherent morbidity and long-term consequences of specific therapies. Selecting the optimal therapeutic approach from an array of choices requires individualization of treatment plans based upon risk stratification, the effectiveness of the treatment, and the likelihood that a patient will experience a treatment-related complication. Radical prostatectomy (RP) remains an excellent treatment option for men with clinically localized prostate cancer.

AB - Introduction Prostate cancer is the most common cancer and the second most common cause of cancer-related death of American men [1]. The American Cancer Society estimates that 186,320 new cases of prostate cancer will be diagnosed and that 28,660 men will die from this disease in the United States in 2008 [2]. The widespread use of prostate-specific antigen (PSA) for prostate cancer screening has led to a substantial decrease in stage at time of diagnosis. Data from the National Cancer Institute's Surveillance, Epidemiology, and End Results program reveal that 91% of diagnosed cancers in the period 1996–2002 were localized to the prostate [1], whereas only 80% are seen in series from previous years. The 5-year expected survival for prostate cancers diagnosed between 1996 and 2002 is 100%, up substantially from 76% between 1984 and 1986 [1]. With today's patients presenting at a younger age and with cancers at a lower stage and lower grade, the management of clinically localized prostate cancer has focused on decreasing the inherent morbidity and long-term consequences of specific therapies. Selecting the optimal therapeutic approach from an array of choices requires individualization of treatment plans based upon risk stratification, the effectiveness of the treatment, and the likelihood that a patient will experience a treatment-related complication. Radical prostatectomy (RP) remains an excellent treatment option for men with clinically localized prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=84927016794&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927016794&partnerID=8YFLogxK

U2 - 10.1017/CBO9780511551994.006

DO - 10.1017/CBO9780511551994.006

M3 - Chapter

SN - 9780511551994

SN - 9780521887045

SP - 43

EP - 57

BT - Prostate Cancer

PB - Cambridge University Press

ER -